SCHEMBL3067369

SCHEMBL3067369

CC(C)N1C=C(c2ccc(N3CCOCC3)cc2)C=CC1C1CCNCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.34
ALDH1A1 P00352 7/20 0.34
KDM4E B2RXH2 4/20 0.34
GAA P10253 2/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
HPGD P15428 1/20 0.34
JAK2 O60674 1/20 0.34
JAK3 P52333 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
PDE3B Q13370 2/20 0.33
PDE3A Q14432 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
KDM5B Q9UGL1 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454571 0.76 CTSC (0.34)
SCHEMBL3455675 0.74 LRRK2 (0.34) MAPTALDH1A1KDM4EGAACHRM2
SCHEMBL3464721 0.68 PIK3CA (0.35) MAPTALDH1A1KDM4EGAACHRM2
SCHEMBL3067368 0.64 ALDH1A1 (0.35) MAPTALDH1A1KDM4EGAACHRM2
SCHEMBL19139501 0.63 SIGMAR1 (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL7082120 0.63 ADRB1 (0.63) MAPTALDH1A1KDM4ENPC1RAB9A
Bromide SCHEMBL6539744 0.61 ADRB1 (0.61) MAPTALDH1A1KDM4ENPC1RAB9A
Hydrochloric Acid SCHEMBL28769210 0.61 ADRB1 (0.61) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL23410248 0.60 HRH1 (0.53) MAPTALDH1A1NPC1RAB9AMEN1
SCHEMBL27569317 0.60 GBA1 (0.53) MAPTALDH1A1KDM4EGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267721-A1 Heterocyclic H3 Antagonists HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-21 US claimed
EP-2166850-A1 NEW HETEOCYCLIC H3 ANTAGONISTS High Point Pharmaceuticals, LLC (US) 2010-03-31 EP disclosed
WO-2008154126-A1 NEW HETEOCYCLIC H3 ANTAGONISTS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267721-A1 Heterocyclic H3 Antagonists HRH3, HRH4, HRH2 MAPT 4831/4885ALDH1A1 3867/4885KDM4E 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.